Kindred Biosciences, Inc. (KIN)
(Delayed Data from NSDQ)
$9.16 USD
+0.33 (3.74%)
Updated May 3, 2019 04:00 PM ET
After-Market: $9.16 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$9.16 USD
+0.33 (3.74%)
Updated May 3, 2019 04:00 PM ET
After-Market: $9.16 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Kindred Biosciences (KIN) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Kindred Bio (KIN) delivered earnings and revenue surprises of -2.78% and -37.39%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Kindred Biosciences (KIN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Kindred Bio (KIN) delivered earnings and revenue surprises of 0.00% and -73.62%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
New Analyst Coverage Make These 5 Stocks Worth a Bet
by Zacks Equity Research
Most investors depend on analysts' research before taking decisions as they fear that lack of information might trigger inefficiencies. Here, analysts play a vital intermediary role with their extensive access to relevant data.
Will Kindred Biosciences (KIN) Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Kindred Biosciences Inc (KIN).
Kindred Biosciences (KIN) Looks Good: Stock Jumps 9.5%
by Zacks Equity Research
Kindred Biosciences, Inc. (KIN) shares rose over 9% in the last trading session.